Summary
AbbVie Inc. reported its first-quarter 2026 financial results, demonstrating robust revenue growth and strategic advancements. Net revenues increased by 12.4% to $15.0 billion compared to the prior year period, driven by strong performance in key therapeutic areas including Immunology and Neuroscience. Despite a notable increase in Research & Development (R&D) expenses, up 20%, the company achieved operating earnings of $4.0 billion and diluted earnings per share (EPS) of $0.39. The company also highlighted significant R&D pipeline progress and strategic investments in manufacturing capabilities. Financially, AbbVie reported $9.4 billion in cash and equivalents, a substantial increase from the prior year-end, supported by strong operating cash flows of $3.8 billion. The company continued its commitment to shareholder returns, declaring a quarterly dividend of $1.73 per share and repurchasing $1.1 billion in stock. Management remains confident in the company's diversified portfolio and pipeline, positioning AbbVie for continued growth and long-term value creation.
Financial Highlights
54 data points| Revenue | $15.00B |
| Cost of Revenue | $4.22B |
| Gross Profit | $10.78B |
| SG&A Expenses | $3.58B |
| Operating Expenses | $11.01B |
| Operating Income | $3.99B |
| Interest Expense | $717.00M |
| Net Income | $695.00M |
| EPS (Basic) | $0.39 |
| EPS (Diluted) | $0.39 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie reported a 12.4% year-over-year increase in net revenues, reaching $15.0 billion for the first quarter of 2026.
- 2Strong performance in Immunology, with Skyrizi and Rinvoq revenues up 30.9% and 23.3% respectively, and Neuroscience, with Vraylar and Botox Therapeutic showing double-digit growth.
- 3Research and Development (R&D) expenses increased by 20% to $2.5 billion, reflecting continued investment in the company's pipeline.
- 4Diluted EPS decreased to $0.39 from $0.72 in the prior year period, primarily impacted by higher operating costs and R&D investments.
- 5The company's cash and equivalents significantly increased to $9.4 billion as of March 31, 2026, driven by robust operating cash flows of $3.8 billion.
- 6AbbVie declared a quarterly dividend of $1.73 per share and repurchased $1.1 billion of its stock during the quarter, demonstrating a commitment to shareholder returns.
- 7Acquired IPR&D and milestones expense increased substantially to $744 million, largely due to an upfront payment for a license agreement with RemeGen.